论文部分内容阅读
为比较高压氧联合精制蝮蛇抗栓酶（Ahalysantinfarctasum．Svate-Ⅲ）与单纯用Svate-Ⅲ治疗脑梗死的效果，对112例确诊为脑梗死的住院患者为治疗组．采用高压氧联合Svate－Ⅲ治疗，至少10次。同时随机抽取同期确诊为脑梗死的住院患者100例为对照组，在一般治疗基础上单纯采用Svate-Ⅲ溶栓治疗。通过对治愈率、有效率及血液流变学变化的观察对2组的疗效进行对比。结果：治疗组的有效率为95．5％．治愈率为64．3％．与对照组相比均有显著性差异（P＜0．01）；治疗后治疗组的全血粘度．血浆粘度．红细胞刚性指数．血浆纤维蛋白原均低于对照组．差异有非常显著性（P＜0．01）。提示高压氧联合Svate-Ⅲ治疗提高了急性期及康复期脑梗死患者的治愈率及有效率．使生活质量提高、康复时间缩短、并发症减少，值得临床推广运用。
In order to compare the effect of hyperbaric oxygen combined with purified Ahalysantinarctasum. Svate-Ⅲ and Svate-Ⅲ alone in the treatment of cerebral infarction, 112 inpatients diagnosed as cerebral infarction were treated. Hyperbaric oxygen combined with Svate-III treatment, at least 10 times. At the same time, 100 hospitalized patients diagnosed as cerebral infarction at the same time were randomly selected as the control group. Svate-Ⅲ thrombolysis was given on the basis of general treatment. Through the cure rate, efficiency and changes in hemorheology observation of the efficacy of the two groups were compared. Results: The effective rate of the treatment group was 95.5%. The cure rate was 64.3%. Compared with the control group, there was a significant difference (P <0.01); after treatment, the whole blood viscosity of the treatment group. Plasma viscosity. RBC rigidity index. Plasma fibrinogen were lower than the control group. The difference was significant (P <0.01). Prompted hyperbaric oxygen combined with Svate-Ⅲ treatment to improve the acute phase and convalescent patients with cerebral infarction cure rate and efficiency. Improve the quality of life, shorten the recovery time, reduce complications, it is worth to promote clinical use.